Retatrutide Batch Documentation: COA & HPLC Guide

What a batch record should identify

• Sample and batch: an identifier that ties the report to the material tested.
• Laboratory and date: who performed the work and when.
• Method: HPLC, mass spectrometry, sterility, endotoxin or another named procedure.
• Result and units: the reported value, limit and any qualification.
• Scope: whether the result concerns purity, identity, content, sterility or another distinct endpoint.

A cropped percentage without the method, batch and report context is not enough to interpret the result. The COA field guide explains the common fields, while the Janoshik verification reference explains report-level checks.

HPLC purity is not content, dose or sterility

HPLC area purity generally describes the relative chromatographic signal assigned to the target peak under a stated method. It does not automatically quantify every component by mass. Water, counterions, residual solvents and material that does not respond comparably at the detection wavelength can affect total mass without appearing as equivalent peaks.

Identity also requires its own evidence, commonly mass spectrometry or another orthogonal method. Sterility and endotoxin are separate endpoints. A high HPLC percentage cannot substitute for a sterility test, stability study, fill-content result or regulatory review.

Archived retatrutide records

These values reproduce the archive exactly; each must be read within its own report scope.

What a COA cannot establish

• that an untested unit or later batch is identical to the tested sample;
• that a compound is approved, lawfully imported or authorized for a particular activity;
• clinical safety, efficacy, dosing or suitability for human or veterinary use;
• sterility unless the report explicitly includes an applicable sterility test;
• stability after conditions outside the report's stated sample history.

Analytical evidence and regulatory authorization answer different questions. For the UAE legal boundary, use the UAE regulatory guide.

Retatrutide approval and trial context

Retatrutide (LY3437943) is an investigational GLP-1/GIP/glucagon receptor agonist. Lilly reported topline TRIUMPH-2 and TRIUMPH-3 results on July 23, 2026 and plans a U.S. Biologics License Application in Q1 2027 after completing its chemistry, manufacturing and controls package. Retatrutide remains unapproved, and a UAE decision would be separate. See the approval tracker and TRIUMPH trial tracker.